Fusion of myoblasts is essential for the formation of multi-nucleated muscle fibres. However, the identity of muscle-specific proteins that directly govern this fusion process in mammals has remained elusive. Here we identify a muscle-specific membrane protein, named myomaker, that controls myoblast fusion. Myomaker is expressed on the cell surface of myoblasts during fusion and is downregulated thereafter. Overexpression of myomaker in myoblasts markedly enhances fusion, and genetic disruption of myomaker in mice causes perinatal death due to an absence of multi-nucleated muscle fibres. Remarkably, forced expression of myomaker in fibroblasts promotes fusion with myoblasts, demonstrating the direct participation of this protein in the fusion process. Pharmacological perturbation of the actin cytoskeleton abolishes the activity of myomaker, consistent with previous studies implicating actin dynamics in myoblast fusion. These findings reveal a long-sought myogenic fusion protein that controls mammalian myoblast fusion and provide new insights into the molecular underpinnings of muscle formation.
Fusion of myoblasts is essential for the formation of multi-nucleated muscle fibres. However, the identity of muscle-specific proteins that directly govern this fusion process in mammals has remained elusive. Here we identify a muscle-specific membrane protein, named myomaker, that controls myoblast fusion. Myomaker is expressed on the cell surface of myoblasts during fusion and is downregulated thereafter. Overexpression of myomaker in myoblasts markedly enhances fusion, and genetic disruption of myomaker in mice causes perinatal death due to an absence of multi-nucleated muscle fibres. Remarkably, forced expression of myomaker in fibroblasts promotes fusion with myoblasts, demonstrating the direct participation of this protein in the fusion process. Pharmacological perturbation of the actin cytoskeleton abolishes the activity of myomaker, consistent with previous studies implicating actin dynamics in myoblast fusion. These findings reveal a long-sought myogenic fusion protein that controls mammalian myoblast fusion and provide new insights into the molecular underpinnings of muscle formation.
Myoblast fusion is a complex and tightly controlled process required for the formation of skeletal muscle fibres 1 . The fusion process must be highly cell-type specific to ensure that fusogenic myoblasts do not form syncytia with non-muscle cell types. Although the transcriptional mechanisms governing skeletal muscle development have been explained in detail [2] [3] [4] [5] , the mechanisms that coordinate myoblast fusion remain incompletely understood, and no muscle-specific protein that directly regulates myoblast fusion has been identified in mammals 6, 7 . In contrast, numerous proteins involved in cell-cell adhesion and actin dynamics have been implicated in myoblast fusion [8] [9] [10] [11] [12] . However, none of these proteins is muscle-specific, necessary and sufficient for mammalian myoblast fusion, suggesting that muscle-specific components of this process remain to be discovered. Here we describe a musclespecific membrane protein called myomaker that is transiently expressed during myogenesis and is both necessary and sufficient to promote myoblast fusion in vivo and in vitro.
Discovery and regulation of myomaker
To search for new skeletal-muscle regulatory genes, we interrogated the National Center for Biotechnology Information UniGene database for genes of unknown function with expression profiles similar to those of MyoD (Myod) and myogenin (Myog), which encode important muscle-specific transcription factors 13, 14 . Among the genes identified in this screen was transmembrane protein 8c (Tmem8c), which had not been previously studied. On the basis of the observations described below, we named this gene myomaker.
During mouse embryogenesis, the myomaker gene is robustly expressed in the myotomal compartment of the somites, and later is expressed in limb buds and axial skeletal muscles ( Fig. 1a and Supplementary Fig. 1a ). Expression of the myomaker gene in the myotomes coincides with expression of other known muscle transcripts, such as Myog and Mcadherin ( Supplementary Fig. 1a ). Myomaker gene messenger RNA (mRNA) is expressed in developing skeletal muscle and is subsequently downregulated upon completion of muscle formation, similar to the expression pattern of Myod and Myog (Fig. 1b ). Myomaker gene expression was not detected in tissues other than skeletal muscle in embryonic day (E)19 embryos ( Supplementary Fig. 1b, c ). In the C2C12 skeletal muscle cell line, the myomaker gene mimics Myog expression, increasing sharply during differentiation and fusion ( Fig. 1c ).
To begin to assess the function of myomaker in skeletal muscle, we obtained embryonic stem cells that contained a LacZ-Neo cassette in intron 1 of the myomaker locus ( Supplementary Fig. 2a ). In this allele, exon 1 of the myomaker gene is spliced to lacZ, preventing expression of a functional myomaker gene transcript. We refer to mice heterozygous and homozygous for the myomaker-lacZ allele as myomaker 1/2 and myomaker 2/2 mice, respectively. 5-Bromo-4-chloro-3-indolyl-b-Dgalactoside (X-gal) staining of myomaker 1/2 mice showed expression of the targeted lacZ allele specifically in skeletal muscle, and not in other muscle tissues or non-muscle tissues ( Fig. 1d and Supplementary  Fig. 2b, c ). Like the endogenous myomaker gene, skeletal muscle expression of the myomaker-lacZ allele declined postnatally (Supplementary Fig. 2d ).
Adult skeletal muscle regenerates in response to damage, owing to the activation of satellite cells, which fuse with residual muscle fibres 4, 5 . We tested whether myomaker gene expression is re-activated during adult muscle regeneration by inducing muscle injury in adult mice. Expression of the myomaker-LacZ allele and myomaker gene mRNA was strongly induced in regenerating muscle after cardiotoxin injury ( Fig. 1e and Supplementary Fig. 2e ). We conclude that the myomaker gene is expressed specifically in skeletal muscle during embryogenesis and adult muscle regeneration.
Myomaker is required for muscle formation
We generated myomaker 2/2 mice by interbreeding of heterozygous mice. Myomaker transcripts were absent in skeletal muscle of myomaker 2/2 mice, confirming that the targeting strategy created a null allelle ( Supplementary Fig. 2f ). Myomaker 2/2 mice were observed at normal Mendelian ratios at E15 and E17.5; however, we failed to detect any live myomaker 2/2 mice at postnatal day 7, suggesting earlier lethality due to muscle dysfunction ( Supplementary Fig. 2g ).
Full-term myomaker 2/2 embryos were alive, as their hearts were beating, but were paralysed and kyphotic with flaccid limbs, hallmarks of skeletal muscle deficiency ( Fig. 2a ). Strikingly, no semblance of differentiated muscle tissue was present in the trunk, limbs or head of myomaker 2/2 animals ( Fig. 2b and Supplementary Fig. 3a, b ).
Muscle formation requires myoblast specification, migration, differentiation and fusion [2] [3] [4] [5] . In principle, dysfunction of one or more of these processes could contribute to lethality and lack of muscle formation in myomaker 2/2 embryos. To begin to define the mechanistic actions of myomaker, we tested the functionality of these processes. The muscle-specific transcription factors, MyoD and myogenin, were expressed normally in myomaker 2/2 embryos ( Supplementary Fig.  3c, d ), suggesting that specification of the skeletal muscle lineage occurred normally in the absence of myomaker. Muscle tissues were present in myomaker 2/2 embryos, indicating that muscle precursor cells were organized appropriately in the absence of myomaker (Supplementary Fig. 3e ). Desmin, a marker of muscle cells, was expressed comparably in myomaker 2/2 and wild-type (WT or 1/1) forelimbs, confirming that myoblast migration was unaltered ( Supplementary  Fig. 3f ). These findings suggested myomaker functions after myoblast specification and migration. Longitudinal sections through hindlimb muscles of myomaker 2/2 embryos at E14 showed the expression of myosin, a muscle differentiation marker, but an absence of multinucleated myofibres (Fig. 2c ). These findings imply that myomaker 2/2 myoblasts can activate muscle-specific gene expression and differentiate, but lack the ability to fuse.
Myomaker 2/2 muscle tissues contained only mono-nucleated cells; however, the cell number was clearly reduced in each muscle analysed. One possible explanation for this decrease is cell death, which has previously been associated with a failure to fuse 15, 16 . Indeed, TdTmediated dUTP nick end labelling (TUNEL) analysis showed increased apoptotic nuclei in muscle forming regions of myomaker 2/2 mice, suggesting that fusion-defective myoblasts are non-viable (Supplementary Fig. 3g ).
Myomaker controls myoblast fusion
To confirm definitively that myomaker functions in myoblast fusion, we used several in vitro differentiation assays using primary myoblasts and the C2C12 muscle cell line. First, we isolated myoblasts from WT and myomaker 2/2 embryos. After 3 days of differentiation, WT myoblasts formed extensive myotubes containing many nuclei ( Fig. 3a) . In contrast, most myomaker 2/2 myoblasts remained mono-nucleated, with only a small percentage forming bi-nucleated myosin positive cells (Fig. 3a, b and Supplementary Fig. 4a ). Quantification of the differentation index showed no differences in the ability of myomaker 2/2 myoblasts to express myosin; however, the fusion index was markedly reduced compared with WT myoblasts ( Fig. 3c and Supplementary Fig. 4b ), even when plated for prolonged periods at higher density than WT myoblasts, indicating that fusion was blocked rather than simply delayed ( Supplementary Fig. 4c ). We conclude that the lack of muscle formation in myomaker 2/2 embryos is due to a block of myoblast fusion, representing the cellular mechanism of myomaker function.
To test whether myomaker was a limiting factor in myoblast fusion, we infected C2C12 cells with a myomaker retrovirus 1 day before differentiation and assessed the consequences on myoblast fusion. Myomaker overexpression caused a marked increase in fusion after 4 days of differentiation (Fig. 3d ). The kinetics of induction of myogenin and myosin, and maximal amounts of expression of the terminal differentiation genes (Myog, Ckm and Myh4), were comparable in myomaker-infected cells and cells infected with a green fluorescent protein (GFP) control virus ( Supplementary Fig. 4d, e ). Despite no differences in expression of muscle differentiation factors, we observed a robust increase in the appearance of myotubes with several nuclei in term WT (1/1) and myomaker 2/2 embryos were dissected and skinned to illustrate the lack of muscle surrounding myomaker 2/2 limbs. b, Paraffin sectioning and H&E staining on tongues show a lack of muscle fibres in E17.5 myomaker 2/2 embryos. c, Longitudinal sections of E14 hindlimb muscles stained with a myosin antibody to determine the multi-nucleation of the muscle cells. WT limbs show myofibres containing several nuclei, which are absent in myomaker 2/2 sections. Scale bars: a, 2 mm; b, 100 mm; c, 40 mm.
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the cultures infected with myomaker, further indicating that myomaker functions specifically in myoblast fusion and does not regulate differentiation per se ( Supplementary Fig. 4f ). Quantification of the fusion index and the number of nuclei per myotube indicated a robust activity of myomaker to increase the fusion capability of these cells ( Fig. 3e and Supplementary Fig. 3g , h). Furthermore, through live cell imaging, we visualized myotube-myotube fusion in myomakerinfected cells (Supplementary Movie 1). These data demonstrate that myomaker is sufficient to enhance C2C12 myoblast fusion. Myomaker is 221 amino acids in length and highly conserved across vertebrate organisms, ranging from fish to humans (Supplementary Fig. 5a ). Analysis of the hydrophobicity of myomaker using a Kyte-Doolittle plot showed extensive regions of hydrophobic character, suggesting this protein may localize to a cellular membrane ( Supplementary Fig. 5b ). Myomaker does not contain predicted N-glycosylation sites. At the carboxy terminus, myomaker possesses a C-A-A-X motif, the consensus for isoprenylation, which mediates membrane association 17 . Myomaker shares limited homology to a family of putative transmembrane hydrolases, named the CREST family 18 , but it lacks a potentially critical histidine residue thought to be important for catalytic activity of hydrolases. The closest relative, Tmem8b, shares homology with myomaker/Tmem8c in three hydrophobic domains; however, Tmem8b is not muscle-specific and its forced expression in C2C12 cells did not promote fusion (data not shown). There is also a related protein in Drosophila, but it is more similar to Tmem8a and Tmem8b than to myomaker/Tmem8c.
To analyse the cellular distribution of myomaker, we engineered a Flag epitope after amino acid 61, in a region of the protein that would not be predicted to perturb the hydrophobic domains ( Supplementary  Fig. 5b ). The Flag-tagged myomaker protein, referred to as myomaker-Flag, was detected in whole-cell lysates, by Flag western blots (Supplementary Fig. 6a ). Retroviral expression of myomaker-Flag in C2C12 cells confirmed that insertion of the Flag epitope did not alter the function of myomaker as assayed by its ability to enhance myoblast fusion ( Supplementary Fig. 6b ). Fractionation of C2C12 cells infected with myomaker-Flag into membrane and cytosolic fractions, showed exclusive localization to the membrane fraction ( Supplementary Fig. 6c ). Myomaker-Flag was readily detected on the surface of myoblasts, by staining live cells with a Flag antibody, a common method used to detect plasma membrane proteins 19 (Fig. 4a ). Moreover, in myoblast cultures undergoing fusion, myomaker-Flag was detected at sites of cell-cell interaction (Fig. 4b ). Immunocytochemistry of fixed and permeabilized C2C12 cells expressing myomaker-Flag showed intracellular vesicle localization of myomaker-Flag, as expected for a membrane protein ( Fig. 4c ). Co-staining with intracellular organelle markers showed some co-localization with endosomes and endoplasmic reticulum ( Supplementary Fig. 6d ), suggesting that myomaker transits through one or more intracellular membrane compartments.
Myoblast fusion requires actin-cytoskeletal reorganization 15, 16, [20] [21] [22] [23] . Treating C2C12 cells with cytochalasin D and lantrunculin B, which perturb the cytoskeleton, completely blocked fusion in cells infected with GFP or myomaker virus, suggesting that actin nucleation is required for the fusogenic function of myomaker ( Supplementary  Fig. 7a ). After treatment with cytochalasin D, myomaker-Flag was properly localized to the membrane, indicating that actin dynamics do not regulate transport of the protein to the cell surface (Supplementary Fig. 7b ). (1/1) and myomaker 2/2 E17 embryos were differentiated for 3 days, and stained for myosin and a nuclear stain (Hoechst). Myomaker 2/2 myoblasts failed to fuse. b, The number of nuclei present in a myosin 1 cell indicates myomaker 2/2 myoblasts cannot form myotubes with three or more nuclei. c, Differentiation index, calculated as the percentage of nuclei in myosin 1 cells, indicated null myoblasts can activate the myogenic program. NS, not statistically significant. d, C2C12 cells infected with a retrovirus encoding GFP or myomaker were induced to differentiate for 4 days then stained with a myosin antibody and Hoechst (nuclei). e, The percentage of myosin 1 cells that contained the indicated number of nuclei. Quantification was performed after 3 days of differentiation in b, c, and after 4 days in e. Scale bars: a, 100 mm; e, 200 mm. Data are presented as mean 6 s.e.m. from three independent experiments. *P , 0.05 compared with WT in b and c, or with GFP-infected cells in e.
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Investigation of the fusogenic functions of myomaker
To understand the mechanism of action of myomaker further, we performed cell-mixing experiments using primary myoblasts from WT, myomaker 1/2 and myomaker 2/2 embryos (Fig. 5a ). After differentiation for 4 days, we visualized b-galactosidase expression from the lacZ allele in myomaker 1/2 and myomaker 2/2 myoblasts to monitor fusion between different myoblast populations. As a co-stain, we used Nuclear Fast Red, which stains a nucleus red and confers a pink appearance in the cytoplasm of cells. Myomaker 1/2 myoblasts formed multi-nucleated myotubes alone, without WT myoblasts, whereas myomaker 2/2 myoblasts failed to fuse (Fig. 5a ). Chimaeric myotubes (blue/pink) were apparent in cultures containing WT and myomaker 1/2 myoblasts, indicating fusion between these two myoblast populations (Fig. 5a ). In cultures containing both WT and myomaker 2/2 myoblasts, we observed myotubes containing LacZ staining emanating from myomaker 2/2 myoblasts (Fig. 5a ). Quantification of the percentage of LacZ 1 myotubes with three or more nuclei showed that myomaker 2/2 myoblasts could only form these structures in the presence of WT myoblasts (Fig. 5b) . We conclude that a cell with a functional copy of the myomaker gene can fuse with a myomaker 2/2 myoblast, suggesting that myomaker is absolutely required on the surface of only one of the fusing muscle cells. We further investigated this possibility by analysing expression of myomaker-Flag in C2C12 cells and detected myomaker-Flag in mono-nuclear C2C12 cells but not in previously fused multi-nucleated myotubes (Fig. 5c ).
To determine whether overexpression of myomaker could allow fusion of fibroblasts, a cell type that lacks fusion capability, we infected 10T1/2 fibroblasts with a GFP virus and either empty virus, as a control, or myomaker virus and then mixed these fibroblasts with C2C12 cells (Fig. 5d ). We did not detect fusion of GFP-empty-virus-infected fibroblasts with myosin-positive cells; however, GFP-myomaker-infected fibroblasts robustly fused with C2C12 cells ( Fig. 5d and Supplementary Movie 2). Quantification of the myotubes expressing both GFP and myosin confirmed a striking ability of fibroblasts expressing myomaker to fuse with myoblasts ( Fig. 5e ).
To control for the possibility that myomaker-expressing fibroblasts were leaky and allowed GFP to diffuse into C2C12 myotubes, we designed a complementary cell mixing experiment in which we tracked fibroblast nuclei by labelling with BrdU, followed by mixing with dsRedinfected C2C12 cells ( Supplementary Fig. 8a ). BrdU-positive nuclei from fibroblasts expressing myomaker were detected within C2C12 myotubes, confirming that myomaker expression was sufficient to direct the fusion of fibroblasts to myoblasts ( Supplementary Fig. 8a, b ). Myomaker was not sufficient to induce fusion of fibroblasts in the absence of myoblasts. The finding that myomaker can promote fusion of fibroblasts to myoblasts but cannot promote fibroblast-fibroblast fusion suggests that additional myoblast cell-surface proteins are required for proper fusogenic engagement of the two membranes.
Discussion
There are several types of membrane fusion, including virus-cell fusion, intracellular vesicle fusion and cell-cell fusion 1 . Similarities exist between different fusion mechanisms, but relatively little is known about cell-cell fusion compared with other fusion processes, or the identities of fusogenic proteins that directly merge intercellular membranes. Our findings identify myomaker as a muscle-specific plasma membrane protein expressed specifically during times of myoblast fusion and required for the formation of multinucleated myofibres. Although surface glycoproteins, including cadherins, b-1 integrin, MOR23 and Adam12 (refs 8-12), have been shown to influence myoblast fusion, myomaker, to our knowledge, is the only muscle-specific protein yet identified that is essential for myoblast fusion in mammals. The absence of multinucleated myofibres in myomaker 2/2 mice demonstrates the requirement of this membrane protein for the formation of all skeletal muscles.
Myoblast fusion is a multistep process requiring intimate cell-cell interaction followed by membrane coalescence accompanied by actin-cytoskeletal dynamics that drive cell merger. Myomaker clearly participates in the membrane fusion reaction, as demonstrated by its reaction. a, Myomaker 1/2 and myomaker 2/2 myoblasts express LacZ, and were either plated alone or mixed with WT myoblasts, induced to differentiate for 4 days and stained with X-gal and Nuclear Fast Red to determine the amount of fusion. Myomaker 1/2 myoblasts, alone or in the presence of WT myoblasts, fused normally, illustrated by myotubes with robust LacZ staining. Myomaker 2/2 myoblasts alone did not fuse. Addition of WT myoblasts to myomaker 2/2 myoblasts resulted in chimaeric myotubes (arrow), indicating fusion between the two cell populations. b, The percentage of LacZ 1 myotubes containing at least three nuclei shows null myoblasts can only form myotubes with three or more nuclei in the presence of WT myoblasts. c, Phalloidin and Flag staining of C2C12 myoblasts after infection with myomaker-Flag illustrates the lack of Flag staining in myotubes. d, 10T1/2 fibroblasts were infected with GFP-retrovirus and either Empty-or myomaker-retrovirus, then mixed with C2C12 cells and differentiated. Myotube formation was monitored by myosin staining, and fusion of fibroblasts was determined by visualization of GFP in myosin 1 myotubes. 
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ability to stimulate myoblast fusion and the fusion of fibroblasts to myoblasts. The inability of myomaker alone to induce fusion of fibroblasts suggests it may require activation or other myoblast proteins to exert its fusogenic activity, probably reflecting a requirement for close membrane apposition to allow membrane merger. Further evidence that other myoblast proteins are required for fusion is our finding that WT myoblasts can fuse with myomaker 2/2 myoblasts. The requirement for interactions between membrane proteins on opposite cells during myoblast fusion has been shown in zebrafish and Drosophila 6,24 , suggesting the molecular regulation of myoblast fusion differs from that of virus-cell fusion, which mainly requires the expression of a fusogenic protein 25 . Changes in the actin cytoskeleton are required for cell-cell fusion 26, 27 . Consistent with this, the activity of myomaker is abolished by cytochalasin D and latrunculin B, which disrupt cytoskeletal events required for fusion, indicating that myomaker depends on the cytoskeleton to exert its function. The discovery of myomaker as a potent myoblast fusion protein opens new opportunities to dissect this fundamental cellular process at a molecular level and to understand how myoblast fusion is perturbed during muscle disease. Moreover, the ability of myomaker to drive fusion of non-muscle cells with muscle cells represents an interesting strategy for enhancing muscle repair.
METHODS SUMMARY
All experimental procedures with animals were approved by the Institutional Animal Care and Use Committee at University of Texas Southwestern Medical Center.
The myomaker/Tmem8c mouse strain used for this research project was created from embryonic stem cell Tmem8c clone (EPD0626_5_C12) obtained from the KOMP Repository (www.KOMP.org) and generated by the Wellcome Trust Sanger Institute 28 .
Whole-mount in situ hybridization was performed as previously described 29 . To isolate muscle progenitors, embryonic limbs were dissected and dissociated in 0.05% Collagenase D (Roche) in PBS at 37 uC for 2-3 h and plated on laminincoated culture dishes.
Retroviral plasmid DNA was generated by subcloning myomaker and Flagtagged myomaker complementary DNAs (cDNAs) into the retroviral vector pBabe-X 30 . GFP and dsRed retrovirus have been described previously 31 .
WT myoblasts were mixed with either myomaker 1/2 or myomaker 2/2 myoblasts in equal ratios, plated on a well of a laminin-coated 12-well plate, and induced to differentiate the next day. 10T1/2 fibroblasts were infected with either GFP-and empty-retrovirus or GFP-and myomaker-retrovirus for 18 h, then mixed with C2C12 cells at a 1:1 ratio.
METHODS
Generation of myomaker 2/2 mice. The myomaker mouse strain used for this research project was created from embryonic stem cell Tmem8c clone (EPD0626_ 5_C12) obtained from the KOMP Repository (www.KOMP.org) and generated by the Wellcome Trust Sanger Institute 29 . This clone was injected into 3.5-day-old C57BL/6 blastocysts by the Transgenic Core Facility at University of Texas Southwestern Medical Center. High-percentage chimaeric male mice were bred to C57BL/6 females to achieve germline transmission of the targeted allele. Myomaker 1/2 mice were intercrossed to generate myomaker 2/2 mice. All experimental procedures involving animals in this study were reviewed and approved by the University of Texas Southwestern Medical Center's Institutional Animal Care and Use Committee. Quantitative real-time PCR (qPCR). Total RNA was extracted from either mouse tissue or cultured cells with TRIZOL (Invitrogen) and cDNA synthesized using Superscript III reverse transcriptase with random hexamer primers (Invitrogen). Gene expression was assessed using standard qPCR approaches with either Power SYBR Green or Taqman Master Mix (Applied Biosystems). We used a 7900HT Fast Real-Time PCR machine (Applied Biosystems) with the following Sybr primers: myomaker-F: 59-ATCGCTACCAAGAGGCGTT-39, myomaker-R: 59-CA CAGCACAGACAAACCAGG-39. Taqman probes for myogenin, MyoD, Ckm and Myh4 were purchased from Applied Biosystems. Expression amounts were normalized to 18S and represented as fold change. In situ hybridizations. For whole-mount in situ hybridization, embryos were fixed overnight in 4% PFA/PBS at 4 uC, then dehydrated in increasing concentrations of methanol and bleached with 6% H 2 O 2 /methanol for 1 h. Embryos were subsequently rehydrated, treated with proteinase K and fixed in 4% PFA, 0.2% glutaraldehyde for 20 min. Pre-hybridization (50% formamide, 53 SSC pH 4.5, 2%SDS, 2% blocking reagent (Roche), 250 mg ml 21 transfer RNA, 100 mg ml 21 heparin) was achieved at 70 uC for 1 h followed by incubation with digoxigeninlabelled probe overnight. Embryos were first washed with solution 1 (50% formamide, 23 SSC pH 4.5 and 1% SDS) three times, six times in solution 2 (100 mM Maleic Acid, 150 mM NaCl, 0.1% Tween-20, pH 7.5), then blocked with consecutive 1 h incubations with 2% blocking reagent/solution 2 and 2% blocking reagent/20% heat-inactivated goat serum/solution 2. To detect bound probe, we performed immunohistochemistry with anti-digoxigenin-alkaline phosphatase antibody (1:2,000, Roche). To develop the AP signal, embryos were washed with solution 1, then incubated with solution 4 (100 mM NaCl, 100 mM Tris-Cl, pH 9.5, 50 mM MgCl 2 , 0.1% Tween-20) with developing reagents (0.25 mg ml 21 NBT (nitro blue tetrazolium chloride) and 0.125 mg ml 21 BCIP (5-bromo-4-chloro-3-indolyl phosphate, toluidine salt, Roche). Lastly, the embryos were washed with solution 4, fixed in 4% PFA/PBS at 4 uC overnight and imaged with a Zeiss 11 stereoscope. Full-length coding sequence was used to generate probes for both MyoD and myomaker by using the digoxigenin labelling kit (Roche) followed by purification with MicroSpin G-25 columns (Amersham).
Radioisotopic in situ hybridization was performed as previously described 32 . Briefly, sections were deparaffinized, permeabilized and acetylated before hybridization at 55 uC with riboprobes diluted in a mixture containing 50% formamide, 0.3 M NaCl, 20 mM Tris-HCl, pH 8.0, 5 mM EDTA, pH 8.0, 10 mM NaPO 4 , pH 8.0, 10% dextran sulphate, 13 Denhardt's solution and 0.5 mg ml 21 transfer RNA. After hybridization, the sections were rinsed with increasing stringency washes, subjected to RNase A (2 mg ml 21 , 30 min at 37 uC) and dehydrated before dipping in K.5 nuclear emulsion gel (Ilford). Autoradiographic exposure ranged from 21 to 28 days. The myogenin probe corresponded to nucleotides 31-638 of the coding sequence, whereas nucleotides 181-811 of the coding sequence were used for the M-cadherin probe. The myomaker probe was full-length coding sequence. 35 S-labelled sense and antisense probes were generated by Sp6 and T7 RNA polymerases, respectively, from linearized cDNA templates by in vitro transcription using a Maxiscript kit (Ambion). Cardiotoxin injury. Cardiotoxin from Naja mossambica mossambica (Sigma) was dissolved in sterile saline to a final concentration of 10 mM, divided into aliquots and stored at 220 uC. Mice were anaesthetized by intraperitoneal injection of 2.5% Avertin at 15 ml g 21 . Mouse legs were shaved and cleaned with alcohol. Tibialis anterior muscles were injected with 50 ml of cardiotoxin with a 26-gauge needle. X-gal staining. For whole-mount X-gal staining, either embryos or tissues were fixed in 4% PFA/PBS (containing 0.01% deoxycholic acid and 0.02% Igepal) for 45 min at 4 uC with gentle shaking then rinsed twice with cold PBS. Samples were stained overnight in staining solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 , 1 mg ml 21 X-gal in PBS) followed by washing twice in PBS and post-fixing with 4% PFA/PBS. For X-gal staining of cryosections or cells in culture, the following procedure was used: fix with 2% gluraraldehyde/PBS, wash three times in 0.1% sodium deoxycholate, 0.2% NP40 Substitute (Fluka), PBS, and incubate in staining solution with differentiation media. These cultures were assayed between 1 and 5 days of differentiation. The actin inhibitors cytochalasin D (Sigma) and lantrunculin B (Sigma) were used at concentrations of 0.3 mM and 0.1 mM, respectively. Subcellular fractionation and western blot analysis. To fractionate C2C12 cells into cytosol and membrane fractions, we first washed a 10 cm dish with cold PBS and lysed the cells by dounce homogenation in hypotonic buffer (10 mM Tris pH 8.0, 1 mM EDTA). The homgenate was centrifuged at 500g for 5 min to pellet nuclei and cell debris. The supernatant was centrifuged at 100,000g for 20 min to pellet membrane structures. The supernatant from this step was the cytosol fraction and the membrane fraction was solubilized in an equal volume of hypotonic buffer 1 1% n-dodecyl b-D-maltoside (DDM, Sigma) for further analyses by immunoblotting. For analysis of whole-cell extracts, DDM solubilization was used (20 mM HEPES, 150 mM NaCl, 2 mM EDTA, 10% glycerol, 1% DDM). For immunoblotting, equal protein amounts were separated on a 12% SDS-PAGE, transferred to a PVDF membrane (Millipore), blocked in 5% milk in TBS-tween and incubated with primary antibodies. The following antibodies were used: M2 Flag (Sigma, 1:1,000), Gapdh (Millipore, 1:10,000), VDAC (Santa Cruz, 1:1,000), a-tubulin (Sigma, 1:1,000), myosin (my32, Sigma, 1:1,000) and myogenin (Developmental Studies Hybridoma Bank, 1:1,000). Cell mixing. WT myoblasts were mixed with either myomaker 1/2 or myomaker 2/2 myoblasts in equal ratios (approximately 1 3 10 5 cells per genotype), plated on a well of a laminin-coated 12-well plate and induced to differentiate the next day. 10T1/2 fibroblasts were infected with either GFP-and empty-retrovirus or GFPand myomaker-retrovirus for 18 h. After infection, cells were washed several times, then trypsinized and mixed with C2C12 myoblasts at a ratio of 1:1 (1 3 10 5 of each cell type) and plated on one well of a six-well plate in differentiation media. GFP and myosin expression was analysed 4 days after differentiation. A similar protocol was performed to assess incorporation of BrdU-labelled fibroblasts into myotubes, with minor modifications. 10T1/2 fibroblasts were incubated with BrdU (Roche) at a final concentration of 10 mM for 18 h. They were then infected with either empty-retrovirus or myomaker-retrovirus and mixed with C2C12 myoblasts that had been infected with dsRed-retrovirus. Time-lapse microscopy. In Supplementary Movie 1, C2C12 myoblasts were infected with GFP and myomaker retrovirus. For Supplementary Movie 2, C2C12 myoblasts were infected with dsRed retrovirus and fibroblasts were infected with GFP and myomaker retrovirus. GFP and dsReD was visualized using a Perkin Elmer Ultraview spinning disk confocal microscope with a chamber for control of temperature and CO 2 . Images were captured every 15 min using Volocity 5.4.0 software. Images were analysed and movies assembled using ImageJ. Quantification and statistics. Each histological analysis of embryonic skeletal muscle was performed on four samples per genotype. The differentiation index was calculated as the percentage of nuclei in myosin-positive cells. The fusion index was calculated as the percentage of nuclei contained in myosin-positive myotubes. Structures had to contain at least two nuclei to be considered a myotube. To quantify fusion between WT myoblasts and either myomaker 1/2 or myomaker 2/2 myoblasts, we calculated the percentage of LacZ 1 myotubes containing at least three nuclei. To quantify fusion between fibroblasts and myoblasts we calculated the percentage of GFP 1 myosin 1 cells or the percentage of BrdU 1 myotube nuclei. For each quantification, at least three independent experiments were performed in duplicate and at least six random fields were imaged per sample. Data are presented as mean 6 s.e.m. Differences between groups were tested for statistical significance using an unpaired two-tailed Student's t-test. P , 0.05 was considered significant. 
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